J
J. Morris
Researcher at Amgen
Publications - 13
Citations - 241
J. Morris is an academic researcher from Amgen. The author has contributed to research in topics: Blinatumomab & Medicine. The author has an hindex of 4, co-authored 7 publications receiving 55 citations.
Papers
More filters
Journal ArticleDOI
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
Franco Locatelli,Gerhard Zugmaier,Carmelo Rizzari,J. Morris,Bernd Gruhn,Thomas Klingebiel,Rosanna Parasole,Christin Linderkamp,Christian Flotho,Arnaud Petit,Concetta Micalizzi,Noemi Mergen,Abeera Mohammad,William Kormany,Cornelia Eckert,Anja Möricke,Mary Sartor,Ondrej Hrusak,Christina Peters,Vaskar Saha,Luciana Vinti,Arend von Stackelberg +21 more
TL;DR: In this article, the authors evaluated event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant.
Journal ArticleDOI
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Giovanni Martinelli,Nicolas Boissel,Patrice Chevallier,Oliver G. Ottmann,Nicola Gökbuget,Alessandro Rambaldi,Ellen K. Ritchie,Cristina Papayannidis,Catherine A. Tuglus,J. Morris,Anthony S. Stein +10 more
TL;DR: In this article, the authors evaluated the long-term durability of blinatumomab in adults with relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukaemia (ALL).
Journal ArticleDOI
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D.J. Pearson,C. Michel Zwaan,E. Anders Kolb,Dominik Karres,Julie Guillot,Su Young Kim,Lynley V. Marshall,Sarah K. Tasian,Malcolm A. Smith,Todd M. Cooper,Peter C. Adamson,Elly Barry,Bouchra Benettaib,Florence Binlich,Anne Borgman,Erica Brivio,Renaud Capdeville,David Delgado,Douglas V. Faller,Linda Fogelstrand,Paula Goodman Fraenkel,Henrik Hasle,Delphine Heenen,Gertjan J.L. Kaspers,Mark W. Kieran,Jan-Henning Klusmann,G. Lesa,Franca Ligas,Silvia Mappa,Hesham Mohamed,Andrew S. Moore,J. Morris,Kerri Nottage,Dirk Reinhardt,Nicole Scobie,Stephen J. Simko,Thomas Winkler,Koen Norga,Gregory H. Reaman,Gilles Vassal +39 more
TL;DR: There is a major need to accelerate the evaluation of innovative medicines, yet drug development continues to be adult-focused, and initiatives continue to accelerate drug development for children with AML and ultimately improve clinical outcomes.
Journal ArticleDOI
Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
Deborah A. Katz,Michael P. Chu,Kevin A. David,Catherine Thieblemont,Nicholas J. Morley,Sharif S. Khan,Yuqi Chen,James Kalabus,J. Morris,Abraham Anderson,Ariel A. Avilion,Eva González-Barca +11 more
TL;DR: This open-label, multicenter, phase 2 study assessed the efficacy and safety of blinatumomab after first-line R-chemotherapy for patients with newly diagnosed, high-risk DLBCL, and the incidence and severity of adverse events (AEs).
Journal ArticleDOI
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Hitoshi Kiyoi,J. Morris,Iekuni Oh,Yoshinobu Maeda,Hironobu Minami,Toshihiro Miyamoto,Toru Sakura,Hiroatsu Iida,Catherine A. Tuglus,Yuqi Chen,Cedric Dos Santos,James Kalabus,Abraham Anderson,Tomoko Hata,Yasuhiro Nakashima,Yukio Kobayashi +15 more
TL;DR: Consistent with global studies, blinatumomab appeared to be safe and efficacious in Japanese adults with R/R ALL and there were no significant associations between maximum cytokine levels or percentage of specific cell types during cycle 1 and response.